RD 30028
Alternative Names: RD3-0028Latest Information Update: 03 Mar 2004
Price :
$50 *
At a glance
- Originator Rational Drug Design Laboratories
- Developer Kuraray; Rational Drug Design Laboratories
- Class Antivirals
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 03 Mar 2004 Discontinued - Preclinical for Respiratory syncytial virus infections in Japan (Inhalation)
- 22 Jun 2001 No-Development-Reported for Respiratory syncytial virus infections in Japan (Inhalation)
- 26 Jun 1998 A preclinical study has been added to the Viral Infections pharmacodynamics section